Oramed Pharmaceuticals Inc.

Regulatory Filings • Jun 11, 2024

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287
	Estimated average burden
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response:	0.5

				or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person* Reznick Yehuda (Last) (First) (Middle) 1185 AVENUE OF THE AMERICAS, THIRD				2. Issuer Name and Ticker or Trading Symbol ORMP ] 3. Date of Earliest T 06/06/2024	ransaction (Month/Day/Year)	ORAMED PHARMACEUTICALS INC. [		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title below)	10% Owner Other (specify below)
FLOOR				4. If Amendment, Date of Original Filed (Month/Day/Year)			Line)	6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person
(Street) NEW YORK	NY	10036						Form filed by More than One Reporting Person
(City)	(State)	(Zip)				Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
						Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)			2. Transaction	2A. Deemed	3.	4. Securities Acquired (A) or		5. Amount of	6. Ownership	7. Nature

	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned Following	Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership
			Code	V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	06/06/2024		A		760	A	(1)	30,560	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and 8. Price of Amount of Derivative Securities Security Underlying (Instr. 5) Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of 760 Restricted Stock Units ("RSUs") that will vest in two equal installments on October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a onefor-one basis.

/s/ Yehuda Reznick	06/10/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.